Quantcast

Industry news that matters to you.  Learn more

Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

World Health Organization Recommends Use of p16 IHC to Help Diagnose High-grade Cervical Disease

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced that the World Health Organization (WHO) has issued new guidance recommending the use of p16 immunohistochemistry (IHC) testing to improve the detection of pre-cancerous cervical disease. In doing so, the WHO is the first global organization to issue written recommendations on the use of p16 after the College of American Pathologists (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP) provided similar guidance in 2012.

Ventana Medical Systems, Inc. and MedImmune Collaborate to Develop a Custom PD-L1 Assay for Immunotherapy Clinical Trials

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, recently announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune’s MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.

Landmark Study of More than 27,000 Women Shows Favorable Results of Roche’s CINtec PLUS Cytology Test

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute.